

Multi-Site ESOS Audits for Global Pharmaceutical Manufacturer

CLIENT | LOCATION

Global Pharma Manufacturer | Multiple UK sites

SECTOR

Various Pharma Manufacturing + R&D sites

PROJECT BRIEF

Since 2015, the UK government has required organisations of sufficient size to measure total energy consumption in the form of ESOS audits, with phase 3 of these audits due to commence in December 2023, it was of the utmost importance to the client that their organisation was fully compliant well before this deadline.

As part of ESOS compliance, a designated Lead Assessor is required to agree the findings of the ESOS audit and confirm compliance with a nominated company director. The client needed a Lead Assessor and an 'evidence pack' to satisfy these criteria and maintain compliance.

SCOPE

EECO2 worked closely with the client to agree a scope of work for the project including:

- A review of previous audit reports and identified actions.
- Detailed energy audits of all on-site office buildings and complex manufacturing areas at 4 agreed UK locations.
- An assessment of transport energy consumption.

METHODOLOGY

In delivering this, EECO2 provided all resources to ensure the client was compliant with ESOS in the UK.

EECO2 supported the client by conducting the energy audits, preparing the required audit reports, managing Pfizer preferred sub-contractors and providing the Lead Assessor to sign off the submission.

SOLUTION

Not only did the client receive output from EECO2 that was sufficient to satisfy the compliance requirement set by the UK government, but additionally, a total of 58 projects across 4 sites were identified, representing a 17% reduction of total site energy consumption. These potential projects were listed in a clear table that quantified each saving in terms of kWh, cost (implementation and saving) and total payback period. Interestingly, HVAC and BMS optimisation posed the greatest opportunity for total kWh reduction.

RESULTS

Energy savings identified (per year):

9,608 MWh (17% reduction)

Total cost savings identified (per year):

£ 933,000

With an average simple payback period of 2.2 years.

